Research evaluation

FINAL RESUME ON THE RESEARCH UNIT:
Immunology of Viral, Auto-immune, Hematological and Bacterial diseases (IMVA-HB)

UNDER THE SUPERVISION OF THE FOLLOWING INSTITUTIONS AND RESEARCH BODIES:
Université Paris-Sud
Commissariat à l'énergie atomique et aux énergies alternatives - CEA
Institut National de la Santé et de la Recherche Médicale - INSERM

EVALUATION CAMPAIGN 2018-2019
GROUP E

Report published on March, 13 2019

In the name of Hcéres[1]:

Michel Cosnard, President

In the name of the experts committee[2]:

Gerd Sutter, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

[1] The president of Hcéres "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

[2] The evaluation reports "are signed by the chairman of the experts committee". (Article 11, paragraph 2).

Tables in this document were filled with data provided by laboratories and supervising bodies in the unit's application and in the Excel files "Données du contrat en cours" and "Données du prochain contrat".

UNIT PRESENTATION

Unit name:	Immunology of Viral, Auto-immune, Hematological and Bacterial diseases
Unit acronym:	IMVA-HB
Requested label:	UMR
Application type:	Restructuration
Current number:	1184
Head of the unit (2018-2019):	Mr Roger LE GRAND
Project leader (2020-2024):	Mr Roger LE GRAND
Number of teams:	5

EXPERTS COMMITTEE MEMBERS

Chair:	Mr Gerd SUTTER, Ludwig-Maximilians-Universität München, Germany
Experts:	Ms Karine CROZAT, Centre d'Immunologie Marseille-Luminy (Deputy Chair, representative of Inserm CSS)
	Ms Anne BULL- MAURER, Inserm/Université de Tours (supporting personnel)
	Ms Francesca CHIODI, Karolinska Institute, Sweden
	Mr Frans KROESE, University of Groningen, The Netherlands
	Ms Nathalie LEBLOND, Université de Lorraine (representative of CNU)

HCÉRES REPRESENTATIVE

Ms Birke BARTOSCH

REPRESENTATIVES OF SUPERVISING INSTITUTIONS AND BODIES

Ms Guia CARRARA, Inserm

Ms Sonia COLETTE-MAATOUK, CEA

Ms Alix DE LA COSTE, CEA

Ms Anne FLURY-HERARD, CEA

Ms Laurence PARMENTIER, Inserm

Mr Didier SAMUEL, Université Paris-Sud

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The UMR1184 was created in 2015 as the result of the association of scientists located at the CEA of Fontenay-aux-Roses research center (former Division of Immuno-Virology/UMRE1) and scientists located at the school of medicine of Université Paris Sud (PSUD) at Bicêtre hospital campus (former U1012). The three institutional bodies of the resulting joint research unit are the Université Paris Sud/Paris Saclay, the CEA and the INSERM.

The unit is implemented in two sites with highly specialized labs and facilities, for preclinical research at Fontenay-aux-Roses research center , and for clinical research at Bicêtre school of medicine.

MANAGEMENT TEAM

Head of unit: Mr Roger Le Grand

HCÉRES NOMENCLATURE

SVE3_1 Microbiologie

SCIENTIFIC DOMAIN

Objective is to favour integrated research programs from basic biology to preclinical and clinical studies in the fields of human infections, human autoimmunity and immunology.

General scientific objectives are to study immune mechanisms related to infections and autoimmune diseases. Final goal is to improve disease control by contributing to vaccine and therapeutic innovation.

UNIT WORKFORCE

	Unit workforce	
	Immunology of viral and auto-immune diseases	
Active staff	**Number 30/06/2018**	**Number 01/01/2020**
Full professors and similar positions	9	8
Assistant professors and similar positions	5	4
Full time research directors (Directeurs de recherche) and similar positions	2	2
Full time research associates (Chargés de recherche) and similar positions	4	4
Other scientists (“Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.”)	23	21
High school teachers	0	0
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	14	14

Permanent staff	**57**	**53**
Non-permanent professors and associate professors, including emeritus	0	
Non-permanent full time scientists, including emeritus, post-docs	4	
PhD Students	12	
Non-permanent supporting personnel	29	
Non-permanent staff	**45**	
Total	**97**	**53**

GLOBAL ASSESSMENT OF THE UNIT

Despite just being created in 2015, the new unit has implemented a strong and clearly visible integrated research program by combining excellent basic immunology, top-notch immune monitoring technologies and unique preclinical models with outstanding clinical investigations in patients' cohorts. The scientific output of the unit as a whole is excellent, both with respect to the total number of scientific articles, the proportion of publications in high impact and in topmost international journals, and the number of collaborative publications with authors from different teams. The outstanding scientific reputation of the unit is attested collectively by: (i) the authority of team members as key speakers at major conferences; (ii) the frequent participation in national and/or international research networks, and (iii) the capability to gain highly competitive research grants.

Connections to the non-academic world are diverse involving local and patient communities, clinical and industrial partners. All teams of the unit have outstanding contracts with pharmaceutical companies and all members of the unit are well immersed in the social, economic and cultural environment. Despite a complex organization, the unit maintains close interactions among all research and technical teams. The work of the unit is organized to provide excellent training through research for students, early career researchers and technical staff; the high technical quality of the training offered with supplementing courses is seen as unique opportunity for personal development.

The strategic aim of the unit is to address major human infections and autoimmune diseases by advancing basic and translational immunological research. The research fields are considered as top priorities and the unit is in a unique position for the development of preclinical models and cutting edge technologies. The addition of teams with complementary and multidisciplinary skills will strongly favour access to new research programs and new opportunities. Expertise and technological capabilities of the unit are at the world class level and must be seen as major European asset to compete with institutions in the USA and Asia in this important field of research.

The evaluation reports of Hceres
are available online : www.hceres.com

Evaluation of clusters of higher education and research institutions
Evaluation of higher education and research institutions
Evaluation of research
Evaluation of doctoral schools
Evaluation of programmes
International evaluation and accreditation

targeting quality
Hcéres

2 rue Albert Einstein
75013 Paris, France
T. 33 (0)1 55 55 60 10

hceres.com @Hceres_ Hcéres